Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Epstein

Showing results (301-310 of 307) with videos related to

Pageof 31
Sort By:
You have reached the last page of results.This site can display upto 307 results.
Journal of Medicinal Chemistry|June 28, 2012
The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancerRichard T Lewis, Christiane M Bode, Deborah M Choquette, et al.
Pharmacoepidemiology and Drug Safety|January 26, 2019
Performance of a computable phenotype for identification of patients with diabetes within PCORnet: The Patient-Centered Clinical Research NetworkAndrew D Wiese, Christianne L Roumie, John B Buse, et al.
Journal of Medicinal Chemistry|February 19, 2008
Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activityMatthew W Martin, John Newcomb, Joseph J Nunes, et al.
Bioorganic & Medicinal Chemistry Letters|March 19, 2011
Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitorsJohn L Buchanan, John R Newcomb, David P Carney, et al.
Journal of Medicinal Chemistry|March 7, 2008
Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activationErin F DiMauro, John Newcomb, Joseph J Nunes, et al.
Journal of Medicinal Chemistry|August 4, 2006
Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activityMatthew W Martin, John Newcomb, Joseph J Nunes, et al.
Journal of Medicinal Chemistry|September 15, 2006
Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activityErin F DiMauro, John Newcomb, Joseph J Nunes, et al.
Pageof 31

Showing results (301-310 of 307) with videos related to

Sort By:
Pageof 31
You have reached the last page of results.This site can display upto 307 results.
Journal of Medicinal Chemistry|June 28, 2012
The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancerRichard T Lewis, Christiane M Bode, Deborah M Choquette, et al.
Pharmacoepidemiology and Drug Safety|January 26, 2019
Performance of a computable phenotype for identification of patients with diabetes within PCORnet: The Patient-Centered Clinical Research NetworkAndrew D Wiese, Christianne L Roumie, John B Buse, et al.
Journal of Medicinal Chemistry|February 19, 2008
Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activityMatthew W Martin, John Newcomb, Joseph J Nunes, et al.
Bioorganic & Medicinal Chemistry Letters|March 19, 2011
Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitorsJohn L Buchanan, John R Newcomb, David P Carney, et al.
Journal of Medicinal Chemistry|March 7, 2008
Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activationErin F DiMauro, John Newcomb, Joseph J Nunes, et al.
Journal of Medicinal Chemistry|August 4, 2006
Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activityMatthew W Martin, John Newcomb, Joseph J Nunes, et al.
Journal of Medicinal Chemistry|September 15, 2006
Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activityErin F DiMauro, John Newcomb, Joseph J Nunes, et al.
Pageof 31